Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction
datasetposted on 2022-04-22, 18:05 authored by Tord Inghardt, Thomas Antonsson, Cecilia Ericsson, Daniel Hovdal, Petra Johannesson, Carina Johansson, Ulrik Jurva, Johan Kajanus, Bengt Kull, Erik Michaëlsson, Anna Pettersen, Tove Sjögren, Henrik Sörensen, Kristina Westerlund, Eva-Lotte Lindstedt
Myeloperoxidase is a promising therapeutic target for treatment of patients suffering from heart failure with preserved ejection fraction (HFpEF). We aimed to discover a covalent myeloperoxidase inhibitor with high selectivity for myeloperoxidase over thyroid peroxidase, limited penetration of the blood–brain barrier, and pharmacokinetics suitable for once-daily oral administration at low dose. Structure–activity relationship, biophysical, and structural studies led to prioritization of four compounds for in-depth safety and pharmacokinetic studies in animal models. One compound (AZD4831) progressed to clinical studies on grounds of high potency (IC50, 1.5 nM in vitro) and selectivity (>450-fold vs thyroid peroxidase in vitro), the mechanism of irreversible inhibition, and the safety profile. Following phase 1 studies in healthy volunteers and a phase 2a study in patients with HFpEF, a phase 2b/3 efficacy study of AZD4831 in patients with HFpEF started in 2021.
Read the peer-reviewed publication
promising therapeutic targetpreserved ejection fractiondaily oral administrationselectivity (> 450phase 2a studybased irreversible inhibitorstructural studies ledcovalent myeloperoxidase inhibitorphase 2irreversible inhibitionhigh selectivitypharmacokinetic studiesclinical studiesvs </vitro </thyroid peroxidasesafety profilepharmacokinetics suitableone compoundlow doselimited penetrationhigh potencyheart failurehealthy volunteersfour compoundsdepth safetyb </animal models5 nm